These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 18751432

  • 1. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.
    Klepzig M, Sauer-Eppel H, Jonas D, Oremek GM.
    Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432
    [Abstract] [Full Text] [Related]

  • 2. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M, Jonas D, Oremek GM.
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [Abstract] [Full Text] [Related]

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Feb; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 4. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G, Sauer-Eppel H, Klepzig M.
    Anticancer Res; 2007 Feb; 27(4A):1961-2. PubMed ID: 17649805
    [Abstract] [Full Text] [Related]

  • 5. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A.
    Cancer Epidemiol Biomarkers Prev; 1993 Feb; 2(2):125-9. PubMed ID: 8467247
    [Abstract] [Full Text] [Related]

  • 6. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E, Joseph DJ, Spry NA, Cohen RJ, Abreu A, Kautto A, Denham JW.
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
    Nakashima J, Sumitomo M, Miyajima A, Jitsukawa S, Saito S, Tachibana M, Murai M.
    J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
    [Abstract] [Full Text] [Related]

  • 10. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S.
    Cancer; 1997 Nov 01; 80(9):1760-7. PubMed ID: 9351545
    [Abstract] [Full Text] [Related]

  • 11. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T, Sakai H, Kanetake H, Saito Y.
    Hinyokika Kiyo; 1999 Apr 01; 45(4):235-9. PubMed ID: 10363141
    [Abstract] [Full Text] [Related]

  • 12. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
    Marin L, Koivula MK, Jukkola-Vuorinen A, Leino A, Risteli J.
    Ann Clin Biochem; 2011 Sep 01; 48(Pt 5):447-51. PubMed ID: 21733929
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma.
    Gao Y, Lu H, Luo Q, Wu X, Sheng S.
    Clin Biochem; 2010 Feb 01; 43(3):291-5. PubMed ID: 19732762
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
    Gascoin-Lachambre G, Trivin C, Brauner R, Souberbielle JC.
    Growth Horm IGF Res; 2007 Jun 01; 17(3):194-200. PubMed ID: 17321775
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival.
    Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA.
    Urol Int; 2006 Jun 01; 76(1):67-71. PubMed ID: 16401924
    [Abstract] [Full Text] [Related]

  • 18. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
    Lüftner D, Jozereau D, Schildhauer S, Geppert R, Müller C, Fiolka G, Wernecke KD, Possinger K.
    Anticancer Res; 2005 Jun 01; 25(3A):1491-9. PubMed ID: 16033050
    [Abstract] [Full Text] [Related]

  • 19. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
    Merseburger AS, Hennenlotter J, Stenzl A, Beger G, Rinnab L, Kuczyk MA, Kuefer R.
    Urol Int; 2007 Jun 01; 79(1):41-3. PubMed ID: 17627167
    [Abstract] [Full Text] [Related]

  • 20. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
    Yokoyama T, Yamamoto M, Shima K, Suzuki K, Sako C, Ito G, Kume M, Maeda M.
    Respirology; 2005 Jun 01; 10(3):300-4. PubMed ID: 15955141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.